Bruker-Chromadex deal 'exciting opportunity for industry'

By Stephen Daniells in Anaheim

- Last updated on GMT

Related tags Material Erectile dysfunction

A new program allowing in-house raw material testing without any up-front capital costs, is 'an exciting opportunity for industry', says Chromadex's VP of corporate development.

At SupplyExpo in Anaheim, CA, Mark Jost,VP corporate development at Chromadex, told that the company's team up with Bruker will allow manufacturers to obtain the in-house capabilities of a contract laboratory without the associated start-up costs.

Co-developed by ChromaDex Corporation and Bruker Optics Inc., the test will initially focus on the near infrared spectrometer (NIR) technology created by Bruker Optics, and uses the phytochemical and botanical reference standard capabilities of ChromaDex.

"The beauty of the whole program is that everyone who participates in this program is on a pay-per-service basis. There are no up-front capital costs. The Bruker NIR unit - which is a very expensive piece of equipment - will be placed in the company's facilities and they will pay for it based on a pay-per-service basis," ​said Jost.

The issue
Deliberate adulteration of products continues to be an issue for the dietary supplements industry and can be either economically motivated adulteration (EMA) or to intensify a specific pharmacological effect. The GMP regulations are widely accepted as a big step in the right direction: The 2007 GMP regulations place the onus on product manufacturers to ensure the quality of their raw materials is sufficient.
Adulteration does still occur, however, and notable examples include adulteration with erectile dysfunction drugs, weight-loss drugs, melamine, and steroid compounds.

Related topics Suppliers GMPs, QA & QC

Related news

Show more

Follow us

Featured Events

View more


View more